First European event on silent occlusions
The first symposium in Europe to focus on silent occlusions and infusion set failures is set to take place later this month.
The event, which will also focus on optimising insulin pump therapy, will be held ahead of the 51st European Association for the Study of Diabetes (EASD) Annual Meeting on September, 14, 2015 in Stockholm.
Leading endocrinologists and diabetes specialists, from Europe and the USA, are coming together for the Optimising Insulin Pump Therapy symposium to consider effective strategies to improve patient and healthcare knowledge around insulin infusion sets.
Insulin flow interruptions, defined in research studies as a continuous rise in inline pressure lasting at least 30 minutes, may lead to unexplained hyperglycaemia in some patients.
Without triggering an occlusion alarm, these events are known as “silent occlusions.”
It is thought approximately two thirds of current insulin pump users have been shown to experience periods of unexplained hyperglycaemia, due to insulin flow interruptions that often go undetected by the pump occlusion alarm system.
Because people with type 1 diabetes do not make insulin, an interruption in flow from a pump may lead to a lack of insulin in the patient that can cause blood glucose levels to rise quickly.
The Optimising Insulin Pump Therapy symposium is being held in advance of the EASD Annual Meeting and takes place on Monday September, 14, 2015 from 14:30 – 17:00 at Stockholmsmässan, Rahbar Hall B, Stockholm, Sweden.